Statistics

Total Visits

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study9

Select a period of time:

Number of views in the range

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study4

Views

Views
May 20241
June 20242
July 20240
August 20241
September 20240
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States4
 

Top cities views

Views
Chicago1